Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
11/2000
11/28/2000US6153614 Piperazinyl pyrimidine dione compounds selective for adrenoceptors
11/28/2000US6153591 Protecting nervous system following focal ischemia and global ischemia; alzheimer's disease, huntington's disease, prion diseases, parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, alopacia, rheumatoid arthritis
11/28/2000US6153581 Drug for recovering renal function
11/28/2000US6153189 Human TRK receptors and neurotrophic factor inhibitors
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070025A1 Methods of using rnase p reaction mechanisms of action
11/23/2000WO2000069859A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
11/23/2000WO2000069847A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069824A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000WO2000069823A1 Ion channel modulating agents
11/23/2000WO2000069821A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000WO2000069820A1 Cyclic amine derivatives and their uses
11/23/2000WO2000069449A2 Conditioned cell culture medium compositions and methods of use
11/23/2000WO2000069421A2 Transdermal therapeutic system (tts) containing tolterodine
11/23/2000WO2000043371A3 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000043354A3 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000023100A3 Genes and proteins predictive and therapeutic for renal disease and associated disorders
11/23/2000WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
11/23/2000WO1999061398A3 24-hydroxyvitamin d, analogs and uses thereof
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2373629A1 Transdermal therapeutic system (tts) containing tolterodine
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372044A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
11/22/2000EP1053014A1 BIOLOGICALLY ACTIVE HEMAGGLUTININ FROM TYPE A $i(CLOSTRIDIUM BOTULINUM) AND METHODS OF USE
11/22/2000EP1052982A1 AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS
11/22/2000EP0669936B1 Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
11/22/2000CN1273833A Chinese medicine for treating nephropathy
11/22/2000CN1058710C Benzamide derivatives, process for prepn. thereof and pharmaceutical compsn. comprising same
11/22/2000CN1058708C Quinolone derivative for treatment of urinary incontinence, its prepn. method and application
11/21/2000US6150526 Piperidine derivative having renin inhibiting activity
11/21/2000US6150508 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
11/21/2000US6150377 Farnesyl protein transferase inhibitors; anticarcinogenic,-tumor and -proliferative agents; also psoriasis, benign prostatic hypertrophy or restinosis; infections facilitated by farnesyl protein transferase, e.g., malaria or hepatitus delta
11/21/2000US6150375 Inhibitors of both of the human 5ar isozymes; benign prostate hyperplasia, male pattern baldness, acne vulgaris, seborrhea, androgenic alopecia, hirsutism and prostate cancer; blocks the conversion of testosterone to 5-alpha-dihydrotestosterone
11/21/2000US6150340 RNA-dependent amidotransferase from Staphylococcus aureus
11/21/2000US6150325 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6149940 Bioavailability; on contact with gastric juices, after rapid and considerable swelling of layers increases considerably in volume, thus, the pharmaceutical preparation remains in the stomach for longer; drug delivery, time release agents
11/21/2000US6149915 Administering a herb salviae miltiorrhizae radix
11/16/2000WO2000068385A2 Novel nucleic acids and proteins with growth hormone activity
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068213A1 Substituted bicyclic compounds
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000067847A2 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067791A1 Ccr4 antagonists in sepsis
11/16/2000WO2000067788A2 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
11/16/2000WO2000067758A1 Remedies for glomerulosclerosis
11/16/2000WO2000067748A1 Remedies for renal failure
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000034331A3 Analogues of glp-1
11/16/2000WO2000034285A3 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
11/16/2000WO2000027377A3 Phosphinate peptide analogs for the treatment of fibrotic disorders
11/16/2000WO2000026224A3 Novel macrolide antibiotics
11/16/2000WO2000020358A3 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000CA2373256A1 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2372871A1 Novel nucleic acids and proteins with growth hormone activity
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372782A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/15/2000EP1051975A1 Dry mix formulation for bisphosphonic acids
11/15/2000EP1051429A1 Ldl related protein and uses thereof
11/15/2000EP1051415A1 Benzamide derivatives as vasopressin antagonists
11/15/2000EP1051403A1 Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/15/2000EP1051173A1 Derivatives of 1,3,4-oxadiazolone
11/15/2000CN1273579A Anthranilic acid analogs
11/15/2000CN1273091A Slowly releasing piperazine ferulate
11/15/2000CN1058394C Method for pharmaceutical based on plants for raising and adjusting tension of smooth muscle organ
11/15/2000CN1058389C Use of compound of benzo-thiophenes
11/14/2000US6147109 Treating impotency; brain, cardiovascular, respiratory system and gastrointestinal disorders
11/14/2000US6147096 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
11/14/2000US6146876 22025, a novel human cyclic nucleotide phosphodiesterase
11/09/2000WO2000066754A1 Protein c derivatives
11/09/2000WO2000066631A1 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066618A1 Integrin receptor antagonists
11/09/2000WO2000066584A1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
11/09/2000WO2000066581A1 Cyanopyrroles as progesterone receptor agonists
11/09/2000WO2000066572A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000WO2000066564A1 Benzimidazolones and analogues and their use as progesterone receptor ligands
11/09/2000WO2000066563A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands
11/09/2000WO2000066556A1 Indoline derivatives as progesterone antagonists
11/09/2000WO2000066555A1 Thio-oxindole derivatives
11/09/2000WO2000066170A1 Prucalopride oral solution
11/09/2000WO2000066135A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000WO2000066134A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000WO2000066112A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics
1 ... 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 ... 562